Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease

Pharmacological Research

Volumn 46, Issue 3, 2002, Pages 203-212

  Martin, Jennifer ^a   Krum, Henry ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

Angiotensin receptor antagonists; Cardiovascular disease; Diabetes; Heart failure; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NATEGLINIDE; NIFEDIPINE; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN; WARFARIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY INJURY; LIPID SOLUBILITY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; VERTIGO;

EID: 0036421319     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00092-0     Document Type: Review

References (73)

1. Lo M, Goldberg M, McCrea J et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-9.
2. Spielberg S, McCrea J, Cribb A et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59: 215.
3. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56 (2): 135-40.
4. Kirk J. Angiotensin-II receptor antagonists: Their place in therapy. Am Family Phys 1999; 59 (11): 3140-8.
5. Kovacs SJ, Wilton JH, Blum RA. Steady state (SS) pharmacokinetics (PK) of irbesartan alone and in combination with fluconazole (F) [abstract PI-59]. Clin Pharmacol Ther 1999; 65 (2): 132.
6. Brunner HR. The new angiotensin II receptor antagonist, irbesartan, pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10: S311-7.
7. Sioufi A, Marfil F, Jaouen A, Cardot JM, Godbillon J, Ezzet F, Lloyd P. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998; 19 (4): 237-44.
8. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997; 62 (3): 272-8.
9. Markham A, Goa KL. Valsartan: A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
10. De Zeeuw D, Remuzzi G, Kirch W. Pharacokinetics of candesartan cilexitil in patients with renal or hepatic impairment. J Hum Hypertens 1997; 11 (Suppl 2): S37-42.
11. Thurmann PA. Valsartan: A novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 2000; 1 (2): 337-50.
12. McMurray J. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart 2001; 86: 97-103.
13. Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998; 20 (6): 1106-14.
14. Lasko BH, Laplante A, Hebert D, Bonnefis-Boyer S. Canadian valsartan study in patients with mild-to-moderate hypertension. Blood Press Monit 2001; 6 (2): 91-9.
15. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, Fitzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18 (5): 797-810.
16. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomised evaluation of strategies for left ventricular dysfunction (RESOLVED) pilot study. The RESOLVD pilot study investigators. Circulation 1999; 100: 1056-64.
17. Riegger G, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, von Behren V, George M, Arens H. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, tolerability, response to exercise trial of candesartan cilexetil in heart failure (STRETCH) Investigators. Circulation 1999; 100 (22): 2224-30.
18. Mazayev V, Fomina I, Kazakov E, Sulimov V, Zvereva T, Lyusov V, Orlov V, Olbinskaya L, Bolshakova T, Sullivan J, Spormann D. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998; 65 (31): 239-46.
19. Granger C, Ertl G, Kuch J, Maggioni A, McMurray J, Rouleau J, Stevenson L, Swedberg K, Young J, Yusuf S, Califf R, Bart BA, Held P, Michelson E, Sellers M, Ohlin G, Sparapani R, Pfeffer M. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000; 139 (4): 609-17.
20. Berry C, Norrie J, McMurray J. Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of Elite-2. Am J Cardiol 2001; 87 (5): 606-7.
21. Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type II diabetes. N Engl J Med 2001; 35 (12): 851-60.
22. Brenner B, Cooper M, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type II diabetes and nephropathy. N Engl J Med 2001; 12: 861-78.
23. Parving H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type II diabetes. N Engl J Med 2001; 345 (12): 870-8.
24. Heart Outcomes prevention Evaluation Evaluation (HOPE) Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
25. Staessen J, Wang J, Lutgarde T. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305-14.
26. Plum J, Bunten B, Nemeth R, Grabensee B. Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 1999; 14 (Suppl 4): 25-7.
27. Mallion JM, Boutelant S, Chabaux P, Baguet JP, Muller M, Meilenbrock S, Heath R, Bodin F. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit 1997; 2 (4): 179-84.
28. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: Long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997; 19 (8): 1263-85.
29. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor lisinopril. J Hum Hypertens 1997; 11 (8): 483-9.
30. Schoenbreger JA. For the Losartan Research Group: Losartan with hydrochlorthiazide in the treatment of hypertension. J Hypertens 1995; 13 (Suppl 1): S43-7.
31. Hegner G, Faust G, Freytag F, Meilenbrock S, Sullivan J, Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997; 52 (3): 173-7.
32. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II receptor antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Phamacol Ther 1996; 60 (3): 341-6.
33. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747-52.
34. Pitt B, Poole-Wilso PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-The losartan heart failure survival study ELITE II. Lancet 2000; 355: 1582-7.
35. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomised evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 1999; 100: 1056-64.
36. Jong P, Demers C, McKelvie R, Liu P. Angiotensin receptor blockers in heart failure: Meta-analysis of randomised controlled trials. JACC 2002; 39 (3): 463-70.
37. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin receptor antagonist, compared with hydrochlorthiazide, atenolol, felodipine ER and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.
38. Nelson EB, Harm SC, Goldberg M, et al. Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, diagnosis, and management. 2nd edn. New York: Raven Press, 1995: 2895-916.
39. Holwerda NJ, Fogari R, Angeli P. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-51.
40. Elliot WJ. For the Eprosartan Study Group. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J Hum Hypertens 1999; 13: 413-7.
41. Pylypchuk G. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32: 1060-6.
42. Chan P, Tomlinson B, Huang T et al. Double-blind comparison of losartan, lisinopril and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37: 101-7.
43. Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorthiazide. J Clin Pharmacol 1997; 37: 101-7.
44. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design. Am Heart J 2000; 140 (5): 727-50.
45. Levy D, Garrison R, Savage D, Kennel W, Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 1561-6.
46. Verdecchia P, Schillaci G, Reboldi G, Porcellati C. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996; 78: 97-202.
47. Schmieder R, Martus P, Klingbel A. Reversal of left ventricular hypertrophy in essential hypertension: Meta-analysis of randomised double-blind studies. JAMA 1996; 275: 1507-13.
48. Thurmann P, Kenedi P, Schmidt A, Harder S, Tietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-42.
49. Lindholm L, Ibsen H, Dahlöf B, et al. The LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study: A randomised trial against atenolol. Lancet 2002; 359 (9311): 1004-10.
50. Stergiou GS, Skeva II, Baibas NM, Roussias LG, Kalkana CB, Achimastos AD, Mountokalakis TD. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000; 35 (6): 937-41.
51. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
52. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
53. Garg R, Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA 1995; 273: 1450-6.
54. Giles T, Kerut D, Roffidal K, Jones L, Given R, Hutchinson M, Tresznewsky H. The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: A substudy of the assessment of treatment with lisinopril and survival in heart failure (ATLAS) trial. Blood Press Monit 2001; 6 (2): 81-4.
55. Pitt B, Zannad F, Remme Cody W, Castaigne R, Perez A, Palensky A, Jolie P, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341 (10): 709-17.
56. Rousseau M et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long term therapy with angiotensin converting enzyme inhibitor. Am J Cardiol 1994; 73: 488-93.
57. Jorde U, Ennezat P, Lisker J. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844-6.
58. Farquharson C, Struthers A. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am College Cardiol 2002; 39 (5): 767-75.
59. Struckman DR, Rivey MP. Combined therapy with and angiotensin ii receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure. Ann Pharmacother 2001; 35: 242-8.
60. Hamroff G, Blaufarb I, Mancini D et al. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol 1997; 30: 533-6.
61. Azizi M, Guyene T, Chatellier G et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29: 634-40.
62. Azizi M, Guyene T, Chatellier G, Menard J. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Clin Exp Hypertens 1997; 19: 937-51.
63. Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, Block AJ. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Practice 2000; 54 (1): 11-4, 16-8.
64. Gremmler BM, Kunert MH, Schleiting H, Ulbricht L. Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. Eur J Heart Failure 2000; 2 (2): 183-7.
65. Murdoch D, McDonagh TA, Farmer R et al. ADEPT: Addition of the AT1 receptor antagonist aprosartan to Ace inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. Am Heart J 2001; 141: 800-7.
66. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999; 99 (20): 2658-64.
67. Marti HP, Pfister M, Frey F, Ferrari P. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. In: Proceedings of the American Society of Nephrology 33rd Annual Meeting and Scientific Exposition, Toronto, Ont., 11-15 October 2000.
68. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild-to-moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23 (8): 1166-79.
69. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan J, Oddou-Stock P. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12(4 Pt 1): 4.
70. Sharpe M, Jarvis B, Goa KL. Telmisartan: A review of its use in hypertension. Drugs 2001; 61 (10): 1501-29.
71. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM. Angiotensin II antagonists for hypertension: Are there differences in efficacy? J Clin Hypertens (Greenwich) 2000; 2 (4): 253-7.
72. Cohn JN, Tognoni G. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
73. 1 receptor antagonists. Curr Therap 1999; 40 (3): 45-51.